Propel Drug-Eluting Sinus Implant Family IBUKI Cohort
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: None, observational standard of care study.
- Who it may be relevant to
- Registry conditions: Chronic Rhinosinusitis (CRS). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Japan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.
Detailed description
This study intends to collect data on the use of the PROPEL family of corticosteroid-eluting implants in the Japanese chronic rhinosinusitis (CRS) population to confirm clinical safety and performance for the PROPEL family of products when used according to IFUs and standard of care in Japan.
Interventions
- Other None, observational standard of care study
None, observational standard of care study
Primary outcome measures
- SNOT-22 total score change [Time frame: baseline to month 3]
Eligibility criteria
Inclusion criteria
- Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements
- Patient has, or is intended to receive or be treated with, an eligible Medtronic product
- Patient is consented within the enrollment window of the therapy received, as applicable
- Patient has a confirmed diagnosis of CRS, and is indicated for FESS per Japan standard practice
- FESS is successfully completed without the occurrence of major/significant complications that may confound study results
- Successful placement of 2 to 4 corticosteroid-eluting implants in the ethmoid or frontal sinus (1 implant per sinus) in accordance with implant IFUs
- NOVAPAK is the only hemostatic packing material placed bilaterally in ethmoid sinuses
Exclusion criteria
- Patient has clinical evidence of disease or a condition expected to compromise survival or ability to complete follow-up assessments through Month 6 (end of study)
- Participation is excluded by local law
- Patient is currently enrolled in, or plans to enroll in, any concurrent study that may confound the PSR results (i.e., no required intervention that could affect interpretation of all-around product safety and/or effectiveness)
- Patient has received biologic medication approved for the treatment of CRSwNP (e.g., dupilumab, mepolizumab) in ≤ 12 weeks prior to the baseline/procedure visit
- Patient is contraindicated in accordance with IFUs of PROPEL family implants and/or NOVAPAK
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Japan · 1 center
- Japanese Red Cross Asahikawa Hospital — Asahikawa
Identifiers
NCT: NCT07546682 · PSR ENT - IBUKI Cohort